A Phase I/II, Open-label, Dose-escalating, Sequential-cohort Study Assessing the Safety, Tolerability, Immunogenicity, and Bioactivity of a Single Intravitreal Injection of DE-122 Injectable Solution for the Treatment of Refractory Exudative Age-related Macular Degeneration

Trial Profile

A Phase I/II, Open-label, Dose-escalating, Sequential-cohort Study Assessing the Safety, Tolerability, Immunogenicity, and Bioactivity of a Single Intravitreal Injection of DE-122 Injectable Solution for the Treatment of Refractory Exudative Age-related Macular Degeneration

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Carotuximab (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions
  • Acronyms PAVE
  • Sponsors Santen Inc
  • Most Recent Events

    • 08 Aug 2017 According to a TRACON media release, company looks forward to the presentation of data from the Phase 1/2 study later this year (2H 2017).
    • 12 May 2017 Planned End Date changed from 1 Apr 2017 to 1 Aug 2017.
    • 12 May 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top